Does suppression of postprandial blood glucose excursions by the α-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?

Diabetes Care

Volumn 19, Issue 6, 1996, Pages 559-563

  Johnson, Andrew B ^a   Taylor, Roy ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; INSULIN; MIGLITOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN SENSITIVITY; MALE; METABOLIC CLEARANCE RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE;

ALPHA-GLUCOSIDASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; FRUCTOSAMINE; GLUCOSAMINE; HUMANS; IMINO PYRANOSES; INSULIN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; TRIGLYCERIDES;

EID: 0029894255     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.6.559     Document Type: Article

References (15)

1. Reaven GM, Hollenbeck CB, Chen Y-DI: Relationship between glucose tolerance, insulin secretion and insulin action in non-obese individuals with varying degrees of glucose intolerance. Diabetologia 32:51-55, 1989
2. Johnson AB, Argyraki M, Thow JC, Jones IR, Broughton D, Miller M, Taylor R: The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients. Diabetic Med 8:243-253, 1991
3. Lebovitz HE: Oral antidiabetic agents: the emergence of α-glucosidase inhibitors. Drugs 44 (Suppl. 3):21-28, 1992
4. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fücker K: Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14:732-737, 1992
5. Heinz G, Komjati M, Korn A, Waldhausl W: Reduction of postprandial blood glucose by the α-glucosidase inhibitor miglitol (BAY m 1099) in type 2 diabetes. Eur J Clin Pharmacol 37:33-36, 1989
6. Samad AH, Ty Willing TS, Alberti KGMM, Taylor R: Effects of BAY m 1099, new α-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo. Diabetes Care 11:337-344, 1988
7. Soeldner SJ: Critical variables in the radioimmunoassay of serum insulin using the double antibody technique. Diabetes 14:771-779, 1965
8. Heding LG: Radioimmunological determination of human C-peptide in serum. Diabetologia 11:541-548, 1975
9. Kingma PJ, Menhere PCA, Sels JP, Nieuwenhuijzen Kruseman AC: α-glucosidase inhibition by miglitol in NIDDM patients. Diabetes Care 15:478-483, 1992
10. Lembcke B, Folsch UR, Gatzemeier W, Lucke B, Ebert R, Siegel E, Creutzfeld W: Inhibition of sucrose- and starch-induced glycaemic and hormonal responses by the α-glucosidase inhibitor emiglitate (BAY o1248) in healthy volunteers. Eur J Clin Pharmacol 41:561-567, 1991
11. Marshall S, Bacote V, Traxinger RR: Discovery of a metabolic pathway mediating glucose induced desensitisation of the glucose transport system. JBC 266:4706-4712, 1991
12. Schnack C, Prager RJ, Winkler J, Mauser RM, Schneider BG, Schernthaner G: Effects of 8-wk α-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care 12:537-543, 1989
13. Jenney A, Proietto J, O'Dea K, Nankervis A, Traianedes K, D'Embden H: Low-dose acarbose improves glycemic control in NIDDM without changes in insulin sensitivity. Diabetes Care 16:499-502, 1993
14. Armitage P, Berry G: The simple crossover design. In Statistical Method in Medical Research. 2nd ed. Oxford, U.K., Blackwell, 1987, p. 222-226
15. Dimitriadis G, Hatziagellaki E, Alexopoulos E, Kordonouri O, Komesodou V, Ganotakis M, Raptis S: Effects of α-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type 1 diabetes mellitus. Diabetes Care 14:393-398, 1991